Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

253.90DKK
10:59am EDT
Price Change (% chg)

kr.2.40 (+0.95%)
Prev Close
kr.251.50
Open
kr.250.50
Day's High
kr.255.80
Day's Low
kr.250.00
Volume
1,587,355
Avg. Vol
--
52-wk High
--
52-wk Low
--

NOVOb.CO

Chart for NOVOb.CO

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 1.02
Market Cap (Mil.): kr.531,309.88
Shares Outstanding (Mil.): 2,112.56
Dividend: 4.50
Yield (%): 1.79

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 26.23 35.80 36.21
EPS (TTM): 9.59 -- --
ROI: 69.67 18.99 18.26
ROE: 76.16 19.76 19.13
Search Stocks

Novo wins EU recommendation for two-in-one diabetes drug

LONDON - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

8:15am EDT

UPDATE 1-Novo wins EU recommendation for two-in-one diabetes drug

* Xultophy combines long-acting insulin deguldec and Victoza

8:13am EDT

Novo sees two-in-one diabetes drug in Europe in first half of 2015

COPENHAGEN - Novo Nordisk, the world's largest insulin maker, said on Friday it expected European Commission marketing authorization for its new two-in-one insulin drug within three months after an EU medicines agency recommended the drug.

7:46am EDT

Novo sees two-in-one diabetes drug in Europe in H1 2015

COPENHAGEN, July 25 - Novo Nordisk, the world's largest insulin maker, said on Friday it expected European Commission marketing authorisation for its new two-in-one insulin drug within three months after an EU medicines agency recommended the drug.

7:38am EDT

Novo wins EU recommendation for two-in-one diabetes drug

LONDON, July 25 - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

7:18am EDT

BRIEF-EU medicines agency backs new drugs from Novo Nordisk, J&J, Gilead

July 25 - The European Medicines Agency: * EU medicines agency says recommends Novo Nordisk diabetes

7:13am EDT

Denmark's Novo A/S enters hearing technology sector with Sonion purchase

COPENHAGEN, July 15 - Danish investment company Novo A/S said it bought hearing technology firm Sonion from Swedish private equity firm Altor, entering a market in which Denmark has been a major player for decades.

15 Jul 2014

Novo Nordisk to double revenue within a decade: deputy CEO

COPENHAGEN - Danish drugmaker Novo Nordisk, the world's biggest insulin maker, expects to more than double its annual revenue within a decade, its deputy chief executive Kaare Schultz told Reuters.

25 Jun 2014

Novo Nordisk diabetes drug appears effective for weight loss: study

- Novo Nordisk's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated.

14 Jun 2014

Novo Nordisk diabetes drug appears effective for weight loss -study

June 14 - Novo Nordisk's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated.

14 Jun 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Wright Reports
$75.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks